SLC6A3 and Parkinson disease: Imaging studies reported decreased uptake of 6-fluoro-l-dopa in the striatum and decreased uptake of dopamine transporter (DAT) in the posterior putamen of patients with CTX, indicating degeneration of the nigrostriatal dopaminergic pathway, which is characteristic of patients with PD (9, 10).